Ocular Allergy

New molecule for allergic conjunctivitis makes debut

First new therapy in nearly a decade offers another option for physicians, patients

Topical hematopoietic therapy viable option for ocular surface disease

Study and use of platelet preparation, other biologics viewed as next frontier

Applying hydrogel technology to sustained-release ocular drugs

Hydrogel technology enables the use of drugs that are known to be efficacious for ocular diseases and conditions when formulated as daily drops or monthly injections, into one-time or several-month dosage forms.

New therapies needed for allergy symptoms, quality of life

October 08, 2017

Half of patients with ocular allergies report experiencing symptoms year-round. While nearly all of them take eye drops to treat their symptoms, the majority report limited or no effect from over-the-counter drops, according to a new survey. The results suggest that new treatment approaches would improve both symptoms and quality of life.

Topical cetirizine latest therapy to treat allergic conjunctivitis

August 04, 2017

Oral cetirizine is one of the most used oral medications for treatment of allergic rhinitis. In May 2017, the FDA approved the first ophthalmic formulation of the second-generation histamine-1 (H1) receptor antagonist for use in treating ocular itching associated with allergic conjunctivitis.

The latest ocular allergy treatments worth watching

July 02, 2017

Progress of ocular allergy treatment in 2017 starts with the fact that this is a mature therapeutic space, with a range of existing choices for clinicians and patients. Progression in therapies from artificial tears to antihistamines and mast cell stabilizers to topical steroids provides a suitable choice for most patients with ocular allergies.

Intracanalicular insert soothes ocular itching in allergic conjunctivitis

June 16, 2017

A phase III study of dexamethasone insert, 0.4 mg (Dextenza, Ocular Therapeutix) found that the sustained-release intracanalicular insert is safe, effective, and well tolerated for treating ocular itching associated with allergic conjunctivitis.

IL-1 receptor inhibitor fails on ocular itching endpoint

August 10, 2016

Isunakinra, an interleukin-1 signaling inhibitor designed for topical ophthalmic administration, did not meet the primary endpoint in a phase III clinical trial for the treatment of moderate-to-severe allergic conjunctivitis.

Alcaftadine superior in reducing itching from grass, tree pollens

July 06, 2016

Alcaftadine ophthalmic solution 0.25% was superior to olopatadine hydrochloride ophthalmic solution 0.2% in reducing the itching related to grass and tree pollens in a multicenter, randomized study in subjects with allergic conjunctivitis.

New ocular allergy drug’s MOA targets inflammation

April 27, 2016

A new, first-in-class, aldehyde-trap topical drop demonstrated rapid onset of action and sustained efficacy with an acceptable safety profile in a phase II clinical trial of patients with moderate-to-severe allergic conjunctivitis.